VSTM
vs
S&P 500
VSTM
S&P 500
Over the past 12 months, VSTM has significantly outperformed S&P 500, delivering a return of +96% compared to the S&P 500's +14% growth.
Stocks Performance
VSTM vs S&P 500
Performance Gap
VSTM vs S&P 500
Performance By Year
VSTM vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Verastem Inc
Glance View
Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company is headquartered in Needham, Massachusetts and currently employs 48 full-time employees. The company went IPO on 2011-11-08. The firm's pipeline is focused on anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition. Its advanced product candidates, VS-6766 and defactinib, are being investigated in both preclinical and clinical studies for the treatment of various solid tumors, including, low-grade serous ovarian cancer (LGSOC), non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic cancer, uveal melanoma, and endometrial cancer. VS-6766 is an orally available small molecule RAF/MEK clamp. VS-6766 is a dual RAF/MEK clamp that blocks both MEK kinase activity and the ability of RAF to phosphorylate MEK. Defactinib is an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase (PYK2) that is being evaluated as a potential combination therapy for various solid tumors.
